Abbott Laboratories
ABT · NYSE
ABT · NYSE
Abbott Laboratories is a diversified healthcare company that sells medical devices, diagnostic products, nutrition products, and established pharmaceutical medicines. Its customers include hospitals, physicians, laboratories, pharmacies, retailers, and consumers. The company earns revenue by selling these products through its healthcare and commercial distribution channels, with medical devices and diagnostics providing exposure to procedure volumes and testing demand, while nutrition and pharmaceuticals add consumer and recurring-care businesses. Segment revenue contributions are not provided in the supplied evidence. Abbott reported $44.3 billion of FY2025 revenue and $6.5 billion of net income, versus $42.0 billion and $13.4 billion, respectively, in FY2024.
Abbott fell 4.39% over the period, from $110.36 to $105.52. Shares slipped on September 1, briefly recovered to $110.47 on September 2, then declined for two sessions before giving back another 2.59% on September 8, the largest daily loss and the week’s heaviest volume at 11.4 million shares. The company received FDA approval for its TactiFlex Duo cardiac-ablation catheter, a potentially supportive product catalyst, but the announcement did not prevent the selloff. Technical pressure was also evident as shares broke below the reported 200-day moving average of $106.31. The supplied evidence does not identify a fundamental negative surprise or broader-market driver explaining the full move.
ABT fell $2.80, or 2.51%, from $111.59 to $108.79 over the week. The stock opened the period at $110.36 after dropping from the prior $112.47 close, then extended its decline to $108.93 on Tuesday. It rebounded 1.41% to $110.47 on Wednesday, as noted by Zacks, but gave back that gain and more on Thursday, closing at $108.79. The supplied evidence does not identify a company-specific earnings release, guidance change, analyst action, or contract that explains the net decline. Abbott did announce a ready-to-feed Similac whole-milk formula launch, while reports of small insider disposals were tax- or award-related, but neither is linked to the trading. The week therefore appears to have moved without an identified company-specific catalyst.
Abbott shares fell $4.17, or 3.58%, over the week, from $116.64 to $112.47. The stock was essentially flat Monday at $116.67, slipped Tuesday, then lost 1.75% Wednesday and another 2.20% Thursday to close at $111.59 before rebounding 0.79% Friday. The available evidence does not identify a negative company-specific catalyst behind the two-day selloff. Instead, Zacks described Thursday’s decline as occurring while the broader market gained, suggesting company-specific underperformance without a stated trigger. Positive product developments, including FDA authorization for Abbott’s Libre Duo dual glucose-ketone sensor and CE Mark approval for the Amulet 360 heart device, did not prevent the decline. Friday’s recovery gave back only part of the Wednesday-Thursday drop.
Abbott Laboratories rose $1.50, or 1.40%, from $107.12 to $108.62 over the week. Trading was uneven: the stock fell $1.66 on August 4 after starting at $107.12, then stabilized on August 5 and rallied $2.25 on August 6 to $107.96. It gave back $0.15 on August 7 before adding $0.81 on August 10 to finish at the weekly high. The clearest company-specific catalyst was Wolfe Research upgrading Abbott to Outperform, an action reported by GuruFocus and MarketBeat. Articles also highlighted Abbott’s Established Pharmaceuticals growth and its Google health and glucose research partnerships, supporting sentiment, although the evidence does not establish their precise trading impact. No broader market driver is supplied.
Abbott shares fell 1.69% over the week, from $107.27 to $105.46. Trading was choppy: the stock rose to $108.00 on July 29, then dropped to $105.61 on July 30, was little changed July 31, rebounded to $107.12 on August 3, and gave back that recovery with a 1.55% decline on August 4. The supplied evidence contains no Abbott-specific announcement, earnings update, analyst action, or guidance change explaining the move. It also provides no broader market or sector catalyst; therefore, the weekly decline is best characterized as trading without an identified company-specific driver.
